Kamada (KMDA) Income from Continuing Operations (2012 - 2026)
Kamada's Income from Continuing Operations came in at $11.12 million for the quarter ended Jun 30, 2026, up 50.7% from $7.38 million a year earlier and up 67.2% from the prior quarter.
Kamada (KMDA) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Kamada reported Income from Continuing Operations of $31.11 million, up 27.1% year-over-year; for the year ended Dec 31, 2025, it came in at $26.74 million, up 84.9% from the prior year.
- Income from Continuing Operations carries a five-year compound annual growth rate of 9.3% (years ended Dec 2020 to Dec 2025).
- Going back by year, Income from Continuing Operations was $14.46 million in the year ended Dec 31, 2024 (+74.6%), $8.28 million in the year ended Dec 31, 2023, -$2.32 million in the year ended Dec 31, 2022 and -$2.23 million in the year ended Dec 31, 2021.
- The figure for the quarter ended Jun 30, 2026 represents the highest quarterly Income from Continuing Operations since the quarter ended Dec 31, 2018.
- Year-over-year, Income from Continuing Operations increased in six of the last eight quarters, with growth averaging 61.6%.
- The fastest year-over-year change in Income from Continuing Operations over five years came in the quarter ended Sep 30, 2023 (growth of 565.9%), and the weakest in the quarter ended Mar 31, 2026 (a decline of 28.2%).
- Business Quant data shows KMDA's Income from Continuing Operations at $6.65 million (quarter ended Mar 31, 2026), $5.91 million (quarter ended Dec 31, 2025) and $7.44 million (quarter ended Sep 30, 2025) in the three quarters before the quarter ended Jun 30, 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 3.09 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 1.10 Bn |
| 10 | Kamada | 488.02 Mn | 197.08 Mn | 22.47 Mn | 11.12 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.12 Mn |
| Mar 31, 2026 | 6.65 Mn |
| Dec 31, 2025 | 5.91 Mn |
| Sep 30, 2025 | 7.44 Mn |
| Jun 30, 2025 | 7.38 Mn |
| Mar 31, 2025 | 9.26 Mn |
| Dec 31, 2024 | 3.81 Mn |
| Sep 30, 2024 | 4.03 Mn |
| Jun 30, 2024 | 4.55 Mn |
| Mar 31, 2024 | 2.51 Mn |
| Dec 31, 2023 | 5.06 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 1.81 Mn |
| Mar 31, 2023 | -1.81 Mn |
| Dec 31, 2022 | 2.94 Mn |
| Sep 30, 2022 | 484,000.00 |
| Jun 30, 2022 | -3.92 Mn |
| Mar 31, 2022 | -1.83 Mn |
| Dec 31, 2021 | -4.66 Mn |
| Sep 30, 2021 | -845,000.00 |
Kamada Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=KMDA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "KMDA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=KMDA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();